Tuberculosis

Treatment Regimens for Latent Tuberculosis Infection Compared

August 01, 2017

Isoniazid, rifampicin monotherapy, combination therapies can prevent active TB in latent TB infection

WHO Adds New Drugs to 2017 Essential Medicines List

By June 12, 2017

A major revision to the antibiotics section includes the categorization of these agents into three groups: ACCESS, WATCH, and RESERVE.

Does Fluoroquinolone Use Delay Diagnosis of Active Tuberculosis?

By October 27, 2016

The use of fluoroquinolones in patients with respiratory infections was found to delay the diagnosis of active pulmonary tuberculosis, according to a study presented at IDWeek 2016.

2016 Treatment of Drug-Susceptible TB Guidelines Released

By August 15, 2016

The 2016 Treatment of Drug-Susceptible Tuberculosis Guidelines have been released as an update to the previous tuberculosis (TB) guidelines published in 2003.

Risks of Suicide Assessed in Cases of Serious Infection

August 11, 2016

Patients hospitalized for serious infections may face an increased risk of suicide, according to research published online in JAMA Psychiatry.

With Increasing Drug Resistance, a Better TB Vaccine Is Even More Critical

By March 24, 2016

Tuberculosis is responsible for causing over 1.6 million deaths per year.

USPSTF: Screen for Latent TB in Those at Increased Risk

March 09, 2016

The U.S. Preventive Services Task Force (USPSTF) recommends screening for latent tuberculosis infection (LTBI) in adults at increased risk.

PCBs, DDT Exposure Impacts Infant Response to TB Vaccine

By December 10, 2015

Babies exposed to chemicals such as PCBs and DDT show weakened responses to the tuberculosis vaccine, according to a new study.

New Priftin Packaging Launched for Active, Latent TB

December 01, 2015

Sanofi announced the launch of new 24- and 32-packs of Priftin (rifapentine) for the treatment of patients with latent and active tuberculosis (TB).

Report Highlights Danger of Drug-Resistant Tuberculosis

November 13, 2015

Cases where the infection isn't thwarted by existing antibiotics are surfacing, researcher says

Risk of TB Highest Within 6 Months of Starting TNF Inhibitors for RA

By November 09, 2015

Patients with rheumatoid arthritis (RA) who initiate TNF inhibitor therapy have an increased risk of tuberculosis, with the highest risk of incidence within the first 6 months, researchers concluded at the 2015 ACR/ARHP Annual Meeting.

Why HIV/TB Coinfected Patients Are Discontinuing Tx at Alarming Rates

By October 11, 2015

Patients with HIV and tuberculosis (TB) coinfection are discontinuing first-line antitubercular therapy (ATT) at disturbingly high rates because of side effects like skin reactions, gastrointestinal symptoms, and hepatotoxicity, according to study findings reported at IDWeek 2015.

Fluoroquinolones Halt Multidrug-Resistant TB in Contacts

July 23, 2015

FQN preventive therapy linked to health system savings and lower mortality versus no therapy

Is Early ART Best for All HIV-TB Patients?

By July 10, 2015

Initiating antitretroviral therapy (ART) within two weeks of tuberculosis (TB) diagnosis improved survival among patients with HIV, TB, and moderately to severely compromised immune systems in research published in the Annals of Internal Medicine.

Fluoroquinolone Preventive Therapy Deemed Beneficial in TB

June 17, 2015

Fluoroquinolone therapy for contacts of individuals with multi-drug resistant tuberculosis is associated with cost savings and reduced incidence of multi-drug resistant tuberculosis, according to a study published in the American Journal of Respiratory and Critical Care Medicine.

Patient With Extensively Drug-Resistant TB May Have Exposed Hundreds

By June 09, 2015

The National Institutes of Health (NIH) has confirmed that while a woman with a rare form of tuberculosis (TB) is currently undergoing treatment, she may have exposed hundreds of people to this treatment-resistant infection.

Imperfect Drug Penetration May Accelerate Pathogen Resistance

By May 20, 2015

A pathogen can develop resistance faster in a "pocket" of the body where only one drug is present compared to where no pockets exist, a new study published in the Proceedings of the National Academy of Sciences has shown.

TB Discovered 133 Years Ago Today, Yet Still One of the World's Deadliest Diseases

By March 24, 2015

The National Institutes of Health (NIH) has issued a statement for World TB Day on the need to effectively diagnose, treat, and cure those infected with tuberculosis (TB).

CDC: Annual Decline in U.S. TB Cases Slowing

March 20, 2015

2013 decrease is smallest seen in more than a decade

Over Two Dozen Test Positive for TB at Kansas High School

March 19, 2015

More than 300 students and staff at Olathe Northwest High School in Kansas were tested last week after a reported case of tuberculosis (TB) at the school.

Culture-Based Screening Algorithm Cuts TB in Immigrants

March 17, 2015

Implementation of a culture-based screening algorithm in 2007 reduced the incidence of tuberculosis (TB) among immigrants and refugees bound for the United States, according to a new study.

Characteristics of Tuberculosis Source Cases Identified

February 25, 2015

In 26 U.S. tuberculosis outbreaks the initial source case-patients had long incubation periods and were characterized by substance abuse, incarceration, and homelessness.

FDA Expands Xpert MTB/RIF Test Use

By February 13, 2015

The Food and Drug Administration (FDA) has granted clearance for the Cepheid Xpert MTB/RIF Assay to help determine if patients with suspected tuberculosis (TB) can be removed from airborne infection isolation with one or two negative test results.

Priftin Gains Latent TB Infection Indication

December 02, 2014

Sanofi announced that the FDA has approved Priftin (rifapentine) in combination with isoniazid for the treatment of latent tuberculosis infection in patients aged ≥2 years at high risk of progression to tuberculosis disease.

Adverse Events Uncovered with New Antibiotics, Antivirals

November 25, 2014

In a new study using the FDA Adverse Event Reporting System database, researchers sought to determine clinically meaningful adverse events reported for 15 relatively new amtimicrobial agents.

New Government Policies on Pathogen Research Issued, But Will They Be Effective?

September 25, 2014

New policy guidelines issued by the White House Office of Science and Technology Policy are calling for U.S. universities to carefully monitor their life sciences research on dangerous pathogens and toxins for both benefits and risks.

Moxifloxacin Regimens: Not Noninferior for Tuberculosis

September 08, 2014

For patients with uncomplicated, smear-positive pulmonary tuberculosis, moxifloxacin-containing regimens over four months are not noninferior to a control regimen.

CDC TB Lab Transfers Resume as New Safety Group Formed

July 25, 2014

After an extensive review by the CDC's internal Laboratory Safety Improvement Working Group, CDC Director Tom Frieden, MD, MPH, has lifted the moratorium on a specific type of material transfer for the CDC's Clinical Tuberculosis Laboratory.

Low Vitamin D Linked to TB Infection in Children

May 09, 2014

Hypovitaminosis D is associated with both latent and active tuberculosis infection in children.

$15 Million Saved Due to Overseas TB Screenings

March 20, 2014

Overseas TB screening of immigrants and refugees saved taxpayers $15 million in medical costs, according to the CDC.